Background
Phase 2, multicenter, single-arm trial (D-ALBA, GIMEMA LAL2116). N=63 adults with newly diagnosed Ph-positive (Ph+) ALL, all ages (median 54, range 24–82). First prospective study of a completely chemotherapy-free frontline strategy in Ph+ ALL: dasatinib induction followed by blinatumomab consolidation, with post-consolidation allo-HSCT (if eligible) or dasatinib maintenance. Published NEJM 2020; long-term 53-month update reported in JCO 2024.
Interventions and follow up
Regimen: Dasatinib 140 mg PO daily + prednisone induction, then blinatumomab 28 µg/d continuous IV consolidation for ≥2 cycles (up to 5), newly diagnosed Ph+ ALL
Primary endpoint: Sustained molecular response (BCR::ABL1 reduction) after 2 cycles of blinatumomab
Median follow-up: 53 months (long-term update)
Primary endpoint: Sustained molecular response (BCR::ABL1 reduction) after 2 cycles of blinatumomab
Median follow-up: 53 months (long-term update)
Results
CR after dasatinib induction (day 85): 98% (62/63)
Molecular response at day 85 (end of induction): 29% (18/62 evaluable)
Molecular response after 2 blinatumomab cycles (primary): 60% (36/60) — endpoint met
Molecular response after all blinatumomab cycles: 72% (progressive deepening)
53-month OS: 75.8% (95% CI 65.0–88.5)
53-month DFS: 80.7% — sustained remissions without chemotherapy
Allo-HSCT in CR1: ~24% (molecularly positive cases prioritized)
Molecular response at day 85 (end of induction): 29% (18/62 evaluable)
Molecular response after 2 blinatumomab cycles (primary): 60% (36/60) — endpoint met
Molecular response after all blinatumomab cycles: 72% (progressive deepening)
53-month OS: 75.8% (95% CI 65.0–88.5)
53-month DFS: 80.7% — sustained remissions without chemotherapy
Allo-HSCT in CR1: ~24% (molecularly positive cases prioritized)
Adverse events
Blinatumomab-related: Grade ≥3 neurologic events ~20% (2 serious, 1 discontinuation); no fatal neurotoxicity; cytokine release syndrome all-grade ~5%
Dasatinib/other: Pleural effusion any grade ~13%; no chemotherapy-type toxicities (alopecia, mucositis, significant nausea); no grade ≥3 hepatic VOD/SOS; treatment-related deaths 0
Dasatinib/other: Pleural effusion any grade ~13%; no chemotherapy-type toxicities (alopecia, mucositis, significant nausea); no grade ≥3 hepatic VOD/SOS; treatment-related deaths 0
Conclusions
Dasatinib + blinatumomab without cytotoxic chemotherapy achieved 98% CR, 60% molecular response after 2 blinatumomab cycles, and 75.8% 53-month OS, with zero treatment-related deaths. This established the chemotherapy-free approach as a viable, highly active frontline strategy for Ph+ ALL, particularly transformative for elderly and frail patients unable to tolerate intensive induction.
Key Limitations
Single-arm, non-randomized design with no comparator regimen; benefit relative to TKI + chemotherapy or TKI + intensive backbone is inferred, not directly tested. Modest sample (N=63). Allo-HSCT and dasatinib maintenance were used post-consolidation, confounding attribution of long-term outcomes to the chemo-free induction-consolidation alone. Optimal post-consolidation strategy (transplant vs maintenance) and the role of more potent TKIs (ponatinib) remain to be defined; relapses, including CNS, still occurred.
Clinical Context
D-ALBA is the foundational trial for chemotherapy-free frontline therapy of Ph+ ALL, combining a TKI with a CD19 bispecific antibody. It is widely regarded as a preferred chemo-free option, especially for older/unfit patients, and is reflected in ESMO and ELN guidance on TKI-plus-immunotherapy strategies. It frames the modern choice between chemo-free dasatinib+blinatumomab and TKI + reduced-intensity chemotherapy (PhALLCON), balancing efficacy, toxicity, and transplant need.
References